menu
    • menu

    Company profile for Viking Therapeutics

    NEW Drugs in Dev: 4
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic pro...
    Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Viking TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12340 El Camino Real, Suite 250 San Diego, CA 92130
    Telephone
    Telephone
    858-704-4660
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.vikingtherapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Viking Therapeutics Completes VK2735 Phase 3 VANQUISH-2 Trial
    Viking Therapeutics Completes VK2735 Phase 3 VANQUISH-2 Trial

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-announces-completion-of-enrollment-in-phase-3-vanquish-2-trial-of-vk2735-302725563.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    Viking Therapeutics Joins Investor Conferences
    Viking Therapeutics Joins Investor Conferences

    06 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-upcoming-investor-conferences-302705936.html

    PR NEWSWIRE
    06 Mar 2026
    Share Share
    Viking Therapeutics Reports Q4 2025 Results and Update
    Viking Therapeutics Reports Q4 2025 Results and Update

    11 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update-302685670.html

    PR NEWSWIRE
    11 Feb 2026
    Share Share
    Viking Therapeutics Reports Q4, FY 2025 Financial Results
    Viking Therapeutics Reports Q4, FY 2025 Financial Results

    04 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-fourth-quarter-and-year-end-2025-on-february-11-2026-302678194.html

    PR NEWSWIRE
    04 Feb 2026
    Share Share
    Viking Therapeutics Announces VK2735 Phase 2 Obesity Results
    Viking Therapeutics Announces VK2735 Phase 2 Obesity Results

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-announces-publication-of-results-from-phase-2-venture-trial-of-dual-glp-1gip-receptor-agonist-vk2735-in-the-journal-obesity-302658213.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Viking Therapeutics Completes VK2735 Maintenance Dosing Trial
    Viking Therapeutics Completes VK2735 Maintenance Dosing Trial

    08 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/viking-therapeutics-announces-completion-of-enrollment-in-maintenance-dosing-clinical-trial-of-vk2735-in-obesity-302655902.html

    PR NEWSWIRE
    08 Jan 2026
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search